Evogene (EVGN) Operating Leases (2018 - 2025)

Evogene (EVGN) has disclosed Operating Leases for 8 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 40.79% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 40.79% year-over-year, with the annual reading at $1.5 million for FY2025, 40.79% down from the prior year.
  • Operating Leases hit $1.5 million in Q4 2025 for Evogene, down from $2.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.7 million in Q4 2021 to a low of $1.1 million in Q4 2023.
  • Historically, Operating Leases has averaged $1.9 million across 5 years, with a median of $1.8 million in 2022.
  • Biggest five-year swings in Operating Leases: soared 119.95% in 2024 and later plummeted 40.79% in 2025.
  • Year by year, Operating Leases stood at $2.7 million in 2021, then crashed by 31.96% to $1.8 million in 2022, then crashed by 37.33% to $1.1 million in 2023, then skyrocketed by 119.95% to $2.5 million in 2024, then tumbled by 40.79% to $1.5 million in 2025.
  • Business Quant data shows Operating Leases for EVGN at $1.5 million in Q4 2025, $2.5 million in Q4 2024, and $1.1 million in Q4 2023.